Argenx data highlight evidence that vyvgart and vyvgart hytrulo drive transformative outcomes for patients with debilitating autoimmune disease

Adhere data show vyvgart ® hytrulo has potential to be first advancement for cidp patients in 30 years

ARGX Ratings Summary

ARGX Quant Ranking